GlassScriptPhysician profile
Keirra Johnson White
NPI 1851065817
$4,191.99
in general payments reported to CMS, 2019-2025
19 companies · $672 in 2025
The $672 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $38.93 · 2022: $1,261 · 2023: $1,448 · 2024: $773 · 2025: $672.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,893.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,892.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $766.32 | 2022-2025 | Lybalvi, Aristada, Aristada Initio |
| Abbvie INC. | $739.17 | 2022-2025 | |
| Corium, LLC | $701.47 | 2022-2023 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $672.05 | 2022-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $279.09 | 2022-2025 | Spravato |
| Ironshore Pharmaceuticals INC. | $168.23 | 2022-2023 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $159.77 | 2021-2025 | Trintellix |
| Neurocrine Biosciences, INC. | $149.49 | 2023-2024 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $113.87 | 2023-2024 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $100.00 | 2023 | Auvelity |
| Braeburn INC. | $86.82 | 2024-2025 | Brixadi |
| Vanda Pharmaceuticals INC. | $64.95 | 2025 | Fanapt |
| Bausch Health US, LLC | $64.40 | 2022 | |
| Indivior INC. | $37.31 | 2024-2025 | Sublocade |
| Idorsia Pharmaceuticals US INC | $20.49 | 2023 | Quviviq |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $20.16 | 2025 | Exxua |
| Lundbeck LLC | $16.91 | 2023 | Rexulti |
| Alfasigma USA, INC. | $15.87 | 2022 | |
| Mannkind Corporation | $15.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keirra White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.